this study was conducted in 2008 at the research field of university of tehran, karaj. the experiment was designed as a randomized complete block design with three replications. treatments were: atrazine 1kg/ha, alachlor 4kg/ha, atrazine+alachlor (1+4) kg/ha, nicosulfuron 80 g ai/ha, furamsulfuron 45g ai/ha, rimsulfuron 25g ai/ha, nicosulfuron+furamsulfuron (80+45) g ai/ha, nicosulfuron+rimsulf...

Autoimmune hemolytic anemia (AIHA) is a clinically relevant complication after allogeneic hematopoietic stem cell transplantation (HSCT). Currently, there is no established consensus regarding the optimal therapeutic approach. Whether AIHA contributes to increased mortality is still somewhat controversial.We investigated the incidence, risk factors, and outcome of post-transplant AIHA in 265 co...

Hospital Physician July/August 2009 21 Ceftriaxone-induced autoimmune hemolytic anemia (AIHA) is an immune-mediated phenomenon caused by ceftriaxone, leading to the destruction of red blood cells (RBCs) and secondary anemia. Approximately 30 years ago, methyldopa and penicillin were the 2 medications most commonly associated with drug-induced AIHA. Currently, most cases of drug-induced AIHA are...

Between 10% and 25% of chronic lymphocytic leukemia (CLL) patients have episodes of autoimmune hemolytic anemia (AIHA) during the course of their disease. The anti-erythrocyte autoantibodies in most cases are polyclonal and express a different heavy chain isotype than the malignant clone, indicating that they are secreted by normal autoreactive B lymphocytes. To further investigate the pathogen...

which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Autoimmune hemolytic anemia (AIHA) is an uncommon disorder characterized by hemolysis mediated by autoanti-bodies directed against self-red blood cells (RBC), with the incidence of 1–3 per 100,000/year and mortality rate of approximately 11% [1, 2]. AIHA is ...

Autoimmune hemolytic anemia (AIHA) is the result of increased destruction of red blood cells (RBCs) due to the production of autoantibodies, and it can be life-threatening. To study the mechanisms that trigger AIHA, we used the Marshall-Clarke and Playfair model of murine AIHA, in which mice repeatedly immunized with rat RBCs develop erythrocyte autoantibodies as well as rat-specific alloantibo...

Autoimmune cytopenias occur in up to 10% of patients during the course of chronic lymphocytic leukemia (CLL), with autoimmune hemolytic anemia (AIHA) the most common, followed by immune-mediated thrombocytopenia (ITP). These disorders may occur at any time during disease course and depend on complex interactions between the malignant clone, impaired T-cell function, microenvironment and the imm...

Autoimmune hemolytic anemia (AIHA) is a rare, but clinically significant complication following hematopoietic stem cell transplantation (HSCT). It is characterized by hemolysis due to antibodies produced by the donor’s immune system against donor red cell antigens. The 3-year cumulative incidence of AIHA is 4.44% in adults; however, 75% of patients develop AIHA during the first post-HSCT year [...

Autoimmune haemolytic anaemia (AIHA) in mantle cell lymphoma (MCL) is a rare but life-threatening complication. To date, there are no relevant data for treatment of AIHA in MCL. Ibrutinib, which has been approved for relapse/refractory MCL, is an immunomodulatory drug inhibiting Th2 activation and consequently the production of autoantibodies. We report a case of MCL with AIHA in which this for...

Spherocytic red cells with reduced membrane surface area are a feature of hereditary spherocytosis (HS) and some forms of autoimmune hemolytic anemia (AIHA). It is generally assumed that membrane loss in spherocytic red cells occurs during their sojourn in circulation. The structural basis for membrane loss in HS is improper assembly of membrane proteins, whereas in AIHA it is due to partial ph...